Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Substantial evidence of effect.

A Lawrence Gould1

  • 1Merck Research Laboratories, West Point, PA 19486, USA. goulda@merck.com

Journal of Biopharmaceutical Statistics
|July 31, 2002
PubMed
Summary
This summary is machine-generated.

Establishing substantial evidence for drug approval requires careful consideration of efficacy and safety. This includes evaluating trial designs, surrogate outcomes, and ethical factors to ensure robust regulatory decision-making.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A framework for assessing the impact of accelerated approval.

PloS one·2022
Same author

Bayesian screening for feature selection.

Journal of biopharmaceutical statistics·2022
Same author

BMA-Mod: A Bayesian model averaging strategy for determining dose-response relationships in the presence of model uncertainty.

Biometrical journal. Biometrische Zeitschrift·2018
Same author

Principled Structured Incorporation of Clinical Knowledge Into Strategic Development Decisions.

Therapeutic innovation & regulatory science·2018
Same author

Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group.

Therapeutic innovation & regulatory science·2018
Same author

Unified screening for potential elevated adverse event risk and other associations.

Statistics in medicine·2018

Area of Science:

  • Pharmacology and Clinical Trials
  • Regulatory Science
  • Biostatistics

Background:

  • Drug development faces pressure for rapid advancement, necessitating a re-evaluation of
  • substantial evidence
  • standards for regulatory approval.
  • Defining substantial evidence for drug efficacy and safety is complex, varying with study populations and conditions.

Purpose of the Study:

  • To discuss considerations in establishing substantial evidence for drug approval.
  • To explore alternative definitions and methods for demonstrating drug efficacy and safety.
  • To address challenges in interpreting clinical trial data for regulatory submissions.

Main Methods:

  • Review of regulatory guidelines (ICH, FDA) and statistical principles.

Related Experiment Videos

  • Analysis of trial designs, including superiority, noninferiority, and equivalence trials.
  • Examination of surrogate endpoints, ethical considerations, and benefit-risk balance.

    • Main Results:

    • Recent guidelines offer alternative definitions of substantial evidence, allowing single studies in some cases.
    • Noninferiority trials require demonstrated assay sensitivity, often supported by external evidence.
    • Case studies (carvedilol, thrombolytics) illustrate interpretation of unexpected findings and alternative strategies.

    Conclusions:

    • Demonstrating substantial evidence involves nuanced interpretation of trial data, considering various factors beyond simple replication.
    • Alternative trial designs and meta-analyses can provide robust evidence for drug approval.
    • Adapting regulatory standards is crucial for timely public health interventions.